Tag: Nerivio
Drug-free migraine treatment gains additional US FDA clearance for preventative use
Theranica has announced that its drug-free Nerivio prescription wearable recently received US Food and Drug Administration (FDA) clearance as a dual-use acute and preventive...
Nerivio neuromodulation device achieves positive results in placebo-controlled migraine trial
Theranica Bio-electronics has announced positive top-line results in its double-blind, randomised, placebo-controlled, multicentre, pivotal clinical trial in the USA. This trial evaluated the efficacy...
Nerivio demonstrates comparable effectiveness to standard-care medications in chronic migraine
Theranica has announced the publication of a new study comparing the effectiveness of Remote electrical neuromodulation (REN) to that of standard-care medications for the acute treatment...
Theranica secures US$45 million through Series C funding round
Theranica has announced the closing of its Series C funding round, with a first closing of US$45 million. New Rhein Healthcare Investors led the...
Study shows positive impact of new in-app feature on Nerivio REN...
A new peer-reviewed study published in Pain Medicine, examining the use of Nerivio’s (Theranica) guided imagery, education and relaxation (GIER) in-app optional behavioural intervention...
Large real-world analysis deems Nerivio safe and effective in migraine treatment
Theranica has announced a new peer-reviewed study analysing the efficacy, safety and sustainability of remote electrical neuromodulation (REN) as a standalone, and medication-adjunct, treatment...
Study indicates safety and efficacy of remote electrical neuromodulation in chronic...
Theranica has announced the publication of a new, peer-reviewed article in Pain Reports detailing a study assessing its novel, drug-free treatment option for chronic...
